Per Clauson
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Diabetes Management and Research, Diabetes Treatment and Management, Pancreatic function and diabetes, Diabetes and associated disorders, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes(2006)630 cited
- → A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education(2007)536 cited
- → Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes(2006)279 cited
- → A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.(1999)119 cited
- → Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial(2013)102 cited
- → Improved glycaemic control with minimal hypoglycaemia and no weight change with the once‐daily human glucagon‐like peptide‐1 analogue liraglutide as add‐on to sulphonylurea in Japanese patients with type 2 diabetes(2009)90 cited
- → Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden(1998)80 cited
- → Insulin Detemir Results in Less Weight Gain than NPH Insulin When??Used in Basal-Bolus Therapy for??Type??2 Diabetes??Mellitus, and this??Advantage Increases with Baseline??Body??Mass Index(2007)69 cited
- → Relationships Between Diabetes Duration, Metabolic Control and β‐cell Function in a Representative Population of Type 2 Diabetic Patients in Sweden(1994)62 cited
- → Lower Risk of Hypoglycemia with Insulin Detemir than with Neutral Protamine Hagedorn Insulin in Older Persons with Type 2 Diabetes: A Pooled Analysis of Phase III Trials(2007)54 cited